Evidence map›Paper›PMID 32301918›Full record

ArticleThe Pediatric infectious disease journal2020

A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts.

Narendra Kumar Arora, Manoja Kumar Das, Ramesh Poluru, Neeraj Kumar Kashyap, Thomas Mathew, John Mathai, Mahesh Kumar Aggarwal, Pradeep Haldar, Thomas Verstraeten, Patrick L F Zuber and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Pediatric infectious disease journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Narendra Kumar AroraFrom the The INCLEN Trust International, New Delhi, India.
Manoja Kumar DasFrom the The INCLEN Trust International, New Delhi, India.
Ramesh PoluruFrom the The INCLEN Trust International, New Delhi, India.
Neeraj Kumar KashyapFrom the The INCLEN Trust International, New Delhi, India.
Thomas MathewDepartment of Community Medicine, Government Medical College, Thiruvananthapuram, Kerala, India.
John MathaiDepartment of Pediatrics, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Mahesh Kumar AggarwalMinistry of Health and Family Welfare, Government of India, New Delhi, India.
Pradeep HaldarMinistry of Health and Family Welfare, Government of India, New Delhi, India.
Thomas VerstraetenP95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium.
Patrick L F ZuberDepartment of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
INCLEN Vaccine Safety Study Group
INCLEN Trust International · INMinistry of Health and Family Welfare · INApple (Israel) · ILGovernment Medical College · INPSG Institute of Medical Sciences & Research · INWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundSafety of pentavalent (DTwP-HBV-Hib) vaccine has been a public concern in India and other countries. This study attempted to document the association of serious adverse events following immunization (AEFI, including hospitalizations and deaths of all causes) with the 3 doses of pentavalent and oral poliovirus (OPV) vaccines.

methodsA cohort of 30,688 infants in 2 south Indian districts were enrolled and followed-up between October 2014 and May 2016, following their first vaccination with DTwP-HBV-Hib and OPV at public health facilities. During weekly follow-ups, by telephone or home visits, the serious AEFIs (hospitalizations and deaths) occurring any time after each vaccination until 4 weeks after third dose were documented. The incidence risk ratios (IRRs) of serious AEFIs in the first (days 0-6) and fourth weeks (days 21-27) after the vaccine doses were compared using the poisson regression analysis.

resultsOf the 30,688 infants enrolled, 30,208 received their third doses of vaccines. During the 4-week periods following each vaccination, there were 365 hospitalizations and 17 deaths. Adjusted incidence risk ratio of 3 doses combined for post-vaccination serious AEFIs during the first week compared with fourth week was 0.8 [95% confidence interval: 0.6-1.0].

conclusionsThere was no increased risk of a serious AEFIs during the first week after any of the 3 doses of pentavalent and OPV vaccination compared with the fourth week. In the absence of any temporal clustering, mortality and hospitalization rates observed in vaccinated infants probably reflects the natural occurrence of such events.

Indexed as

Diphtheria-Tetanus-Pertussis VaccineFemaleHaemophilus VaccinesHospitalizationHumansIndiaInfantMalePoliovirus Vaccine, InactivatedProspective StudiesVaccinationVaccines, CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPoliovirus Vaccine, InactivatedVaccines, Combined

Identifiers

PMID32301918
PMCPMC7170438
OpenAlexW3017377563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.